NEW YORK (PRWEB) April 30, 2020
With hospitals losing revenue as they struggle under the burden of COVID-19 cases, the U.S.-based medical services firm ERI Global Inc. has assembled an international network of companies that manufacture and distribute COVID-19 tests in a way that is 100 percent reimbursable to hospitals.
Presently, U.S. hospitals are hemorrhaging cash and laying off medical staff, as hospitals are focused on COVID-19 cases and are prevented from conducting other medical services and surgeries that finance hospital operations and staff salaries.
Meanwhile, manufacturers are struggling to match the capacity they have to produce testing kits and other supplies with the right customers – all while millions of Americans await their chance to receive a test.
“I find it unfathomable that the entire world is in dire need of all of these products immediately, the manufacturers cannot keep up with demand, and the hospitals are either furloughing thousands of employees or closing-down all together,” said ERI President Bobbie Celler. “There is a better way and by working together in a more organized manner, we can provide these vital tests more efficiently to where they are needed most.”
One solution is a little-noticed facet in the recent stimulus packages from Washington, D.C. Last week, the White House and the Centers for Medicare & Medicaid Services announced that COVID-19 testing kits will be reimbursed at $100 per test for healthcare facilities and other medical providers. Celler said this essentially makes them free to hospitals that use the proper procedures. (For more information on the CMS action, see this link.)
“CMS has made a critical move to ensure adequate reimbursement for advanced technology that can process a large volume of COVID-19 tests rapidly and accurately,” CMS Administrator Seema Verma said in the announcement last week. “This is an absolute game-changer for nursing homes, where risk of coronavirus infection is high among our most vulnerable.”
ERI’s organization has assembled FDA-approved domestic and global manufacturers, as well as foreign governments and medical consortiums, into the largest group purchasing initiative since the outbreak of the coronavirus. This, coupled with a procurement/reimbursement hybrid, allows U.S. hospitals to obtain a 100-percent reimbursement while simultaneously providing the American public with desperately needed testing products.
“We are all looking for ways to navigate through these unprecedented times,” Celler said. “We know that by banding together we can draw on our many strengths to tackle this crisis.”
For more information on gaining access to FDA-approved COVID-19 testing kits, contact supplychain@EriGlobal.com to be added to the list.
About ERI Global:
Based in New York, NY, ERI Global, Inc. has contracted with over 400 Hospitals and generated more than $500M in gross revenue since 2011 and has worked with many of the Top 30 United States Healthcare Systems in identifying lost insurance revenue and transforming healthcare systems’ revenue cycles. For more information, visit eriglobal.com.
Media Contact:
Richard Mullins
(813) 228-0652 x1127
rmullins@tuckerhall.com